与阿托瓦斯塔丁相关的肝损伤:在达丁重新挑战后的结果
Blandine Bertin1, Valentine Lacotte1, Jean-Luc Cracowski2,3
1Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.
Fundamental & clinical pharmacology
|February 15, 2026
概括
在阿托瓦斯塔丁肝损伤后,他类药物重复使用往往会导致复发. 然而,水友性他类药物,如罗斯瓦斯塔丁或普拉瓦斯塔丁似乎更安全地重新引入,复发风险较低.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 药品安全 药品安全
背景情况:
- 类固醇诱导的肝损伤 (DILI) 是常见的,但通常是轻微的.
- 在阿托瓦斯塔丁诱导的肝损伤后,关于他类药物的安全性数据是有限的.
研究的目的:
- 调查阿托瓦斯塔丁诱导的肝损伤后的他类药物复发的安全性和复发率.
- 识别具有潜在较低复发风险的他类药物.
主要方法:
- 法国药监数据库中的病例的回顾性分析.
- 包括经过记录的阿托瓦斯塔丁或替代性他类药物重新引入的患者和至少2周的随访.
- 肝损伤模式的分类 (胆固醇,细胞分解,混合) 和严重程度分级.
主要成果:
- 分析了26例阿托瓦斯塔丁DILI的病例,随后重新引入了他类药物.
- 在16名接受阿托瓦斯塔丁治疗的患者中,有12名患者出现了肝损伤的复发 (发病时间缩短).
- 在10名患者中,有2名患有替代性他类药物 (罗斯瓦斯塔丁,西姆瓦斯塔丁) 的复发;在小队伍中,水友性他类药物 (罗斯瓦斯塔丁,普拉瓦斯塔丁) 没有复发.
结论:
- 药物诱导的肝损伤经常在阿托瓦斯塔丁重新使用后复发.
- 水友性他类药物,特别是罗苏瓦斯塔丁和普拉瓦斯塔丁,在重新使用时可能会更好地耐受.
- 需要对更大的队列进行进一步的研究,以确认在因他类药物引起的肝损伤后,水友性他类药物的安全性.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
282
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
282
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
212
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Atherosclerosis III: Management
459
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
459
Drug Toxicity: Allergic Reactions
16
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
16
Drug toxicity: Idiosyncratic Reactions
21
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
21


